ADC Field Blooms, new technologies evolve like a rolling tide, propelling biomedicine into high-speed mode. This is the best of times. As early as the early 20th century, Paul Ehrlich first proposed the concept of “magic bullets”; however, the first ADC drug, Mylotarg® (gemtuzumab ozogamicin), was not approved until nearly a century later. Every cloud … Read more
Antibody-drug conjugates (ADCs) are formed by linking monoclonal antibodies targeting specific antigens with small molecule cytotoxic drugs through linkers, combining the powerful killing effects of traditional small molecule chemotherapy with the tumor-targeting properties of antibody drugs. ADCs consist of three main components: the antibody responsible for selectively recognizing cancer cell surface antigens, the drug payload … Read more
Introduction Antibody-drug conjugates (ADC) combine the high specificity of monoclonal antibodies with the high potency of small molecule cytotoxic drugs to enhance the targeting of cancer therapies and reduce side effects. Compared to traditional antibodies or antibody fragments, ADCs can release highly active cytotoxins within tumor tissues, theoretically leading to higher efficacy. ADCs have undergone … Read more
Key Content Preview:In recent years, antibody-drug conjugates (ADCs) have developed rapidly. As of August 2023, there are a total of 15 ADCs on the market globally, with over 1200 drugs under research. In June this year, Nature Biotechnology published a brief report titled “ADCs’ Revival”, highlighting the “breakthrough momentum” of ADCs in new drug development. … Read more
Antibody-drug conjugates (ADC), also known as “magic bullets,” use monoclonal antibodies (Antibody) to deliver small molecule drugs (Drug) directly to tumor cells expressing specific antigens through a linker (Conjugate). In recent years, ADC drugs have rewritten the treatment guidelines for blood cancers, breast cancer, ovarian cancer, and lung cancer, providing patients with significantly improved clinical … Read more
In the early 20th century, Paul Ehrlich first proposed the famous “magic bullet” theory, suggesting that drugs could be developed to specifically target pathogens without affecting normal tissues and cells. Subsequently, the concept of antibody-drug conjugates (ADCs) was introduced, combining the target specificity of monoclonal antibodies with the anti-tumor properties of cytotoxic molecules. After decades … Read more
ADC (Antibody-drug conjugate) is a new type of drug for cancer treatment. It is a complex formed by combining anti-tumor drugs with antibodies, allowing for precise delivery of the drug into tumor cells, thereby achieving targeted treatment of tumor cells. However, with the widespread application of ADCs, research has found that the issue of ADC … Read more
By | Little Medicine Monster Global ADC Pipeline Status As of December 6, 2023, a total of 1166 ADC pipelines have been developed globally, with 524 pipelines under research and 16 approved drugs (including two TDM-1 biosimilars). The abandonment rate of pipelines is as high as 54% (1166-524-16/1166). Among the 524 pipelines under research, over … Read more
Introduction Antibody-drug conjugates (ADC) are formed by linking monoclonal antibodies targeting specific antigens with small molecule cytotoxic drugs through linkers, combining the powerful killing effect of traditional small molecule chemotherapy with the tumor targeting ability of antibody drugs. Since ADCs first entered clinical trials in the mid-1990s, they have developed into a very successful oncology … Read more
Introduction Antibody-drug conjugates (ADC) are formed by linking monoclonal antibodies targeting specific antigens with small molecule cytotoxic drugs through linkers, combining the powerful killing effect of traditional small molecule chemotherapy with the tumor targeting ability of antibody drugs. Since the first ADC, Gemtuzumab-ozogamicin (brand name: Mylotarg), was approved for the treatment of CD33-positive acute myeloid … Read more